Compounds for enzyme inhibition
US9205126B2 · kind B2 · utility
7Cited by
72References
40Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 26, 2013 |
| Grant date | Dec 8, 2015 |
| Priority date | — |
| Expiry date | Oct 3, 2033 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.